-
Inhibrx Reports Q3 2026 Financial Results: Key Updates and Strategic Outlook
NASDAQ: $INBX Overview of Q3 2026 Financial Performance Inhibrx, a biopharmaceutical company focused on developing therapeutic candidates for various oncology and orphan diseases, has officially released its financial results for the third quarter ending September 30, 2026. The report provides transparency into the company’s ongoing research, development investments, and operational status as they continue to…
-
Angel Yeast Achieves Prestigious EcoVadis Silver Medal: A Milestone in Global Sustainability
A Testament to Sustainable Growth Angel Yeast has officially reached a new milestone in its corporate responsibility journey. The company has been awarded the EcoVadis Silver Medal, a recognition that places the organization within the top 10% of the world’s most sustainable companies evaluated by the platform. What This Achievement Means The EcoVadis rating is…
-
Innovent Showcases Preclinical Data of its First-in-Class IL-6 x TL1A Bispecific Antibody at ACR Convergence 2026
PALO ALTO, Calif. and SUZHOU, China, Nov. 12, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular,… Source: Read More
-
Revolutionizing Emergency Care: Keikku and ACEP Partner to Enhance Clinical Decision Support
Transforming Emergency Medicine Through Digital Integration In a significant move for healthcare technology, Keikku and the American College of Emergency Physicians (ACEP) have officially entered into a collaboration agreement. This partnership aims to bridge the gap between complex emergency medicine guidelines and the fast-paced environment of the emergency department by embedding clinical decision support directly…
-
Transformative Biotech Bolsters Leadership Team with Dr. Nicholas Meyerson
A Strategic New Appointment Transformative Biotech, a leader in the biotechnology sector, has officially announced the appointment of Dr. Nicholas Meyerson to its executive team. This strategic move marks a significant milestone for the company as it continues to advance its mission of developing innovative solutions in the biotech landscape. Who is Dr. Nicholas Meyerson?…
-
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.
Q4’26 reported revenue growth of 5% year over year and 2% on an organic basis FY’26 reported revenue growth of 5% year over year and 2% on an organic basis FY’27 reported revenue expected to range from $648 to $660 million FY’27 organic revenue growth expected to range between 3% to 5%… Source: Read More
-
A New Frontier in Heart Health: Ribo Biotherapeutics Advances SR122 Clinical Trials
Revolutionizing Lipid Management The fight against cardiovascular disease is taking a significant step forward as Ribo Biotherapeutics recently announced the submission of a clinical trial application in Europe for its innovative drug candidate, SR122. This move marks a major milestone in the company’s mission to address the complex challenges of mixed and severe dyslipidemia. Understanding…
-
Edgewise Therapeutics Announces Participation in Upcoming Investor Conferences
Connecting with the Investment Community Edgewise Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for rare muscle disorders, has officially announced its upcoming participation in key investor conferences. These events serve as a vital platform for the company to provide updates on its strategic initiatives and ongoing research programs. Marking the Calendar Management from…
-
GlycoNex Reaches Major Milestone with Japanese Regulatory Submission for Denosumab Biosimilar
A New Step Forward for Biosimilar Access GlycoNex Inc. has officially announced a significant milestone in its product development pipeline. The company has successfully submitted a New Drug Application (NDA) to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for SPD8, their highly anticipated denosumab biosimilar. Understanding the Significance of SPD8 Denosumab is a…
-
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren’s disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience data to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more… Source: Read More
-
A Breakthrough in Oncology: VS PharmTech Enhances Cancer Treatment Efficacy
A New Frontier in Precision Medicine The landscape of cancer therapy is witnessing a significant advancement as VS PharmTech unveils promising data regarding their innovative approach to oncology. Their latest research highlights a critical achievement in modern medicine: the ability to significantly boost the efficacy of cancer treatments without the burdensome increase in toxicity that…
-
Halozyme Projects Stability Amid New Medicare Drug Price Negotiation Rules
NASDAQ: $HALO Ensuring Long-Term Revenue Predictability In a significant announcement for stakeholders, Halozyme Therapeutics has officially reaffirmed its financial outlook regarding the impact of the Medicare Drug Price Negotiation Program. Despite evolving regulatory landscapes, the company projects zero to minimal impact on its royalty revenue through at least 2035. Understanding the Regulatory Context The company’s…
-
A Breakthrough in Hepatitis B: AusperBio Reports Sustained Functional Cure
A New Milestone in Chronic Hepatitis B Research In a significant development for global health, AusperBio has announced encouraging results from its clinical studies regarding chronic hepatitis B (CHB). The company reported that patients have maintained a sustained functional cure for up to 15 months after stopping all antiviral treatment. Understanding the Clinical Results The…
-
Co-Diagnostics Highlights Global Tuberculosis Initiatives and CoSara Advancements
NASDAQ: $CODX Strategic Focus on Global Health Co-Diagnostics, Inc. recently announced its participation in three major global tuberculosis (TB) events throughout November. These engagements underscore the company’s commitment to addressing one of the world’s most persistent infectious disease challenges through advanced molecular diagnostics. CoSara’s Progress in India A central theme of the announcement is the…
-
Excelra Named a Leader in Everest Group’s Pharmaceutical R&D IT Services PEAK Matrix® 2026
A Milestone in Pharmaceutical Innovation The pharmaceutical industry is constantly evolving, and the digital infrastructure supporting it is more critical than ever. We are proud to share that Excelra, a global leader in data-driven life sciences solutions, has been recognized as a Leader in the prestigious Everest Group’s Pharmaceutical R&D IT Services PEAK Matrix® Assessment…
-
Bio-Techne Announces Quarterly Cash Dividend: What Shareholders Need to Know
NASDAQ: $TECH A Commitment to Shareholder Value Bio-Techne Corporation (NASDAQ: TECH) has officially announced that its Board of Directors has declared a quarterly cash dividend. This move reflects the company’s ongoing dedication to delivering value to its investors while maintaining its position as a global leader in the life sciences sector. Dividend Details The company…
-
A $10 Million Breakthrough: Researching the Roots of Breast Cancer Relapse
Advancing the Fight Against Cancer The Montefiore Einstein Comprehensive Cancer Center (MECCC) has received a significant $10 million grant to tackle one of the most persistent challenges in oncology: breast cancer relapse. This substantial funding aims to fuel cutting-edge research into why breast cancer can return, often years after initial treatment. The Mission: Decoding Dormancy…
-
Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure
COPENHAGEN, Denmark, Nov. 3, 2026 /PRNewswire/ — Cambiotics ApS (“Cambiotics”), the company developing beneficial bacteria designed to support the natural elimination of unwanted compounds, such as per- and polyfluoroalkyl substances (PFAS, known as “forever chemicals”), announced today… Source: Read More
-
Durchbruch in der Kardiologie: Transform-II-Studie zeigt Erfolg bei sirolimusbeschichteten Ballons
Eine neue Ära für die interventionelle Kardiologie In der Behandlung von verengten Herzkranzgefäßen gibt es eine wegweisende Entwicklung: Die Ergebnisse der internationalen Transform-II-Studie belegen, dass sirolimusbeschichtete Ballone (SCB) nach einem Jahr genauso wirksam sind wie herkömmliche medikamentenfreisetzende Stents (DES). Was bedeutet das für Patienten? Diese Erkenntnis könnte die Art und Weise, wie Kardiologen bei koronaren…
-
CJ Bio Set to Showcase Future-Ready Animal Nutrition at EuroTier 2026
Innovating the Future of Animal Nutrition As the global agricultural landscape faces new challenges regarding sustainability and efficiency, CJ Bio is preparing to take the stage at EuroTier 2026. The company has officially announced its participation in this premier international trade fair, where it plans to unveil a suite of ‘future-ready’ animal nutrition solutions. Focusing…
-
Bridging Global Expertise: Aphranel Hosts European Physicians in China for Clinical Exchange
Strengthening International Medical Collaboration In a significant move to foster global health innovation, Aphranel recently hosted a delegation of distinguished European physicians in China. This visit served as a platform for high-level clinical exchanges, aimed at sharing medical expertise and exploring advanced therapeutic strategies between different healthcare systems. Focus on Knowledge Sharing The program was…
-
A Milestone in ALS Research: Zhimeng Biopharma Completes Patient Enrollment for CB03-154
A Significant Step Forward in ALS Treatment In a major development for the neuroscience community, Zhimeng Biopharma has officially announced the completion of patient enrollment for its investigational drug, CB03-154. This marks a pivotal milestone in the company’s ongoing Phase 2/3 clinical trial focused on treating Amyotrophic Lateral Sclerosis (ALS). Understanding the Clinical Trial ALS…
-
Recognizing Excellence: Medicilon Honored with the ‘Client Partnership Excellence Award’ by Revolution Medicines
Celebrating a Strategic Alliance In a significant milestone for the biotechnology sector, Medicilon, a leading preclinical research organization, has been officially recognized for its outstanding contributions to Revolution Medicines. The company was recently presented with the prestigious ‘Client Partnership Excellence Award’, a testament to its unwavering commitment to accelerating drug discovery and development. The Power…
-
BioArctic Announces New Nomination Committee Ahead of Annual General Meeting
Setting the Stage for Corporate Governance BioArctic AB, the biopharmaceutical company known for its innovative research into neurodegenerative diseases, has officially announced the composition of its Nomination Committee. This process is a key step in preparing for the company’s upcoming Annual General Meeting (AGM). The Role of the Nomination Committee The primary responsibility of the…
-
Optimizing Clinical Research: Resonant Clinical Solutions Launches New Asset Management Programs
Revolutionizing Sample Management in Clinical Trials Managing clinical trial samples is a complex logistical challenge that demands precision and foresight. Resonant Clinical Solutions has officially announced a new series of asset management programs designed to provide sponsors with the critical information and support necessary to refine their sample storage strategies. Strategic Support for Complex Inventories…